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Abstract  
BACKGROUND/OBJECTIVE: Insulin signals, via the regulation of key enzyme 
expression, both suppress gluconeogenesis and enhance lipid synthesis in the liver. 
Animal studies have revealed insulin signaling favoring gluconeogenesis suppression to 
be selectively impaired in steatotic livers. However, whether, and if so how, such 
selective insulin resistance occurs in human steatotic livers remains unknown. Our aim 
was to investigate selective insulin resistance in human livers with non-alcoholic fatty 
liver disease (NAFLD).  
SUBJECTS/METHODS: We examined mRNA expressions of key molecules for 
insulin signaling, gluconeogenesis and lipogenesis in human liver biopsy samples 
obtained from 51 non-diabetic subjects: 9 healthy controls and 42 NAFLD patients, and 
analyzed associations of these molecules with each other and with detailed pathological 
and clinical biochemistry data. 
RESULTS: In NAFLD patients, insulin receptor substrate (IRS)-2 expression was 
decreased, while those of key enzymes for gluconeogenesis were increased. These 
alterations of IRS-2 and gluconeogenesis enzymes were induced both in simple steatosis 
(SS) and non-alcoholic steatohepatitis (NASH), while these expression levels did not 
differ between SS and NASH. Furthermore, alterations in the expressions of IRS-2 and 
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gluconeogenesis enzymes showed strong negative correlations and were concurrently 
induced in the early histological stage of NAFLD. In contrast, fatty acid synthase (FAS) 
expression was not decreased in NAFLD, despite IRS-2 down-regulation, but correlated 
strongly with IRS-1 expression. Furthermore, no histological scores were associated 
with these molecules. Thus, IRS-1 signaling, which is not impaired in NAFLD, appears 
to modulate FAS expression. 
CONCLUSION: These analyses revealed that selective insulin resistance is present in 
human NAFLD livers and occurs in its early phases. The effect of insulin, during the 
IRS step, on gene expressions for lipogenesis and gluconeogenesis are apparently 
distinct and preferential down-regulation of IRS-2 may contribute to selective resistance 
to the suppressive effects of insulin on gluconeogenesis. 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic triglyceride 
accumulation not due to alcohol consumption (<20 g ethanol per day), resulting in 
steatosis and hepatic inflammation 1. Approximately 20% of patients with non-alcoholic 
simple steatosis (SS) will progress to non-alcoholic steatohepatitis (NASH) with 
histological changes such as lobular inflammation and/or hepatocellular ballooning. 
Furthermore, approximately 20% of patients with NASH will progress to cirrhosis 2. It 
is well known that nearly all patients with NAFLD have hepatic insulin resistance, 
which increases the risk of developing type 2 diabetes 3.  
The liver is the central organ for whole-body carbohydrate and lipid homeostasis and 
hepatic insulin signaling is essential to maintaining the metabolism of these nutrients. 
Insulin secreted in the fed state promotes glycogen synthesis and lipogenesis but 
suppresses hepatic glucose production by inhibiting gluconeogenesis and 
glycogenolysis 4. On the other hand, suppression of insulin secretion in fasted states 
promotes gluconeogenesis and glycogenolysis, resulting in normoglycemia. Insulin 
binds to the insulin receptor (IR) and activates its tyrosine kinase, thereby promoting 
tyrosine kinase phosphorylation of IR substrates (IRSs), such as IRS-1 and IRS-2, both 
of which are abundantly expressed in hepatocytes. Tyrosine-phosphorylated IRS-1 and 
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IRS-2 bind to and activate phosphatidylinositol-3-kinase, subsequently activating a 
serine/threonine kinase Akt 5. Akt-dependent phosphorylation and nuclear exclusion of 
forkhead box-containing protein O subfamily-1 suppress expressions of 
glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), 
resulting in the inhibition of hepatic glucose output 6. Moreover, insulin stimulates the 
pathway through up-regulation of fatty acid synthase (FAS) 7 as well as up-regulating 
glucokinase (GCK) which catalyzes the first and rate-limiting step of glycolysis, 
thereby increasing hepatic lipogenesis 8 (Supplementary Figure 1).  
Major impacts on insulin signaling are observed under conditions of hepatic steatosis. 
The molecular mechanism of the alteration in insulin signaling in the liver has been 
intensively investigated using a number of experimental animal models of obesity 
and/or hepatic steatosis. First, hepatic IRS-2 expression was found to be down-regulated 
in these animal models, contributing to the development of hepatic insulin resistance. In 
addition, insulin-induced down-regulations of G6Pase and PEPCK are known to be 
impaired, resulting in enhanced gluconeogenesis 6. In contrast to impairment of the 
suppressive effects of insulin on gluconeogenesis, insulin signaling through the hepatic 
lipogenic pathway is reportedly not suppressed, instead being stimulated 7, 9. Thus, 
insulin resistance in the steatotic liver is considered to be limited to the pathway 
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involving suppression of hepatic glucose production, which is referred to as selective 
insulin resistance 10. However, the proposed molecular mechanism of selective insulin 
resistance is based on experimental data obtained from animal models, mainly mice fed 
a high-fat diet 11. In contrast, human data on hepatic gene expressions, including IRS-2 
12-14 and gluconeogenic enzymes 15, 16, in patients with NAFLD are scarce and 
controversial.  
Therefore, in the present study, we aimed to investigate hepatic gene expressions 
involved in insulin signaling integrity for comparison between healthy subjects and 
NAFLD patients. We further examined the relationships among expressions of these key 
molecules, the histological severity of NAFLD and clinical blood biochemistry data. 
Based on the results obtained, we herein propose a molecular mechanism underlying 
selective insulin resistance. 
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MATERIALS AND METHODS 
Subjects   
A retrospective analysis of clinical data and histological information was performed 
on patients with biopsy-proven NAFLD during the period from September 2005 to 
April 2014 in Tohoku University Hospital and Yamagata University Hospital. Patients 
were excluded from the analysis if they consumed more than 20g of alcohol per day, or 
had evidence of liver diseases with other etiologies, such as viral hepatitis, autoimmune 
hepatitis, primary biliary cirrhosis, hemochromatosis, drug-induced liver disease and 
other secondary hepatic diseases. In total, 82 patients were included in the analysis. 
Because our aim was to investigate selective insulin resistance in NAFLD, 38 patients 
who had been diagnosed as having diabetes were excluded. Diabetes was defined as 
HbA1c ≥ 6.5% (48 mmol/mol), fasting plasma glucose ≥ 126 mg/dL or random plasma 
glucose ≥ 200 mg/dL (11.1 mmol/L), or currently receiving medical treatment for 
diabetes, according to the American Diabetes Association criteria for the diagnosis of 
diabetes 17. Two patients who had been taking eicosapentaenoic acid (EPA) were also 
excluded from the analysis, because EPA reportedly exerts beneficial effects on hepatic 
steatosis18 and steatohepatitis 19 by reducing the expression of sterol responsive element 
binding protein-1c (SREBP-1c) 20. Thus, ultimately, we analyzed 42 NAFLD patients. 
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Diagnoses of NAFLD were histologically confirmed in all of these patients, as 
described below. As controls, we retrospectively enrolled 9 healthy subjects who had 
been donors for liver transplantation during the same period in Tohoku University 
Hospital. All control subjects were confirmed to have normal liver functions and 
histologically normal findings. The Ethics Committee at the Tohoku University School 
of Medicine approved the research protocol, which was performed in accordance with 
World Medical Association Declaration of Helsinki. Patients gave written informed 
consent prior to inclusion in the study. 
 
Histological liver analyses  
Routine needle liver biopsies were performed in all patients and wedge liver biopsies 
were performed in all donors for histological analyses. Formalin-fixed, 
paraffin-embedded (FFPE) liver sections were stained with hematoxylin-eosin and 
Masson’s trichrome. A single highly experienced pathologist (K.M.), unaware of the 
gene expression data, evaluated all of the biopsy specimens, confirmed the diagnoses 
and classified NAFLD patients according to the classification by Matteoni et al 21, as 
follows: type 1: fatty liver alone, type 2: fat accumulation and lobular inflammation, 
type 3: fat accumulation and ballooning degeneration, or type 4: fat accumulation, 
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ballooning degeneration and either Mallory-Denk bodies or fibrosis. Type 1 and 2 were 
classified as SS, types 3 and 4 as NASH. As a result, this study included 19 patients 
with SS and 23 with NASH. In addition, histological features were graded 
semi-quantitatively according to Kleiner’s score 22, which consists of the degree of 
steatosis (0-3 points), lobular inflammation (0-3 points) and hepatocellular ballooning 
(0-2 points) as well as Brunt’s staging classification 23, which represents the degree of 
fibrosis (0-4 points). Additionally, we calculated the NAFLD activity score as the sum 
of points for steatosis, lobular inflammation and hepatocellular ballooning 22. The 
patients were classified into four groups: no steatosis (0 points), simple steatosis (1-2 
points), borderline-NASH (3-4 points) and NASH (5-8 points).  
 
Biochemical analyses  
Fasting plasma glucose, serum insulin, total cholesterol, triglycerides, aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT), type IV collagen, 
hyaluronic acid and HbA1c were measured in patients with NAFLD. Fasting plasma 
glucose, serum total cholesterol, triglycerides, AST, ALT, and HbA1c were measured in 
healthy control subjects. Some of the laboratory data were lacking in some of the 
patients and controls. HOMA-IR was calculated as fasting glucose (mg/dL) x fasting 
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insulin (µU/mL)/405. Since the HOMA-IR cut-off point for identifying insulin 
resistance in healthy Japanese was reported to be 1.7 24, subjects with HOMA > 1.7 
were considered to have insulin resistance in the present study. 
 
Gene expression analyses  
Total RNA was isolated from samples of FFPE liver tissues (10 µm sections) by 
using an RecoverAllTM Total Nucleic Acid Isolation Kit for FFPE (Applied Biosystems, 
Foster City, CA) according to the manufacture’s instructions. FFPE samples were 
deparaffinized using a series of xylene and ethanol washes, then subjected to a rigorous 
protease digestion for recovery of RNA. The recovered RNAs were suitable for 
real-time RT-PCR analysis, based on past reports 25, 26. cDNA was synthesized with 
approximately 300 ng of total RNA using a High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA). With 60% amounts of the obtained cDNA, 
we performed cDNA pre-amplification reactions with primers of target genes using the 
Taqman Preamplification Master Mix Kit (Applied Biosystems Foster City, CA) in 
order to increase the sensitivity of real-time PCR analysis of the FFPE samples. The 
amplified products were 1/20 diluted, and quantitative PCR was performed using an 
ABI 7700 sequence detection system and Taqman PCR Master Mix (Applied 
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Biosystems Foster City, CA). The following ABI-inventoried TaqMan gene expression 
assays were used; IR, IRS-1, IRS-2, PEPCK, G6Pase, GCK and FAS. In addition, 
expressions of two isoforms of IR, IR type A (IR-A) and IR type B (IR-B), were 
compared using isoform specific ABI-inventoried TaqMan gene expression assays. 
Cyclin-dependent kinase inhibitor 1B (CDKN1B) was used as an internal control in 
accordance with the manufacturer’s recommendation. Relative changes in gene 
expressions were determined using the 2-ΔΔCt method. ΔCt refers to the cycle number at 
which the transcripts were detectable (Ct) normalized to the cycle number of CDKN1B 
27 
 
Statistical methods 
The presence or absence of a normal distribution was verified using the Shapiro-Wilk 
W test. The normalized mRNA levels were log-transformed before data analysis due to 
non-normal distributions. Data, expressed as means ± SEM, were compared by ANOVA 
with Tukey-Kramer post hoc testing, and correlations were assessed employing 
Pearson’s test. A level of P<0.05 was considered significant. Analyses were carried out 
with JMP 11.2 Pro statistical analysis software (SAS Institute, Cary, NC). HbA1c values 
were missing for 5 subjects (3 control and 2 SS subjects). Fasting serum insulin and 
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HOMA-IR values were missing for 3 of the SS subjects, serum type IV collagen values 
were missing for 17 subjects (11 SS and in 5 NASH subjects), and serum hyaluronic 
acid values were missing for 15 subjects (12 SS and 2 NASH subjects). The sample size 
calculation was based on a previous study comparing hepatic IRS-2 mRNA expression 
between NAFLD and normal subjects 12. Assuming an 80% difference with a standard 
deviation of 45% between NAFLD and subjects free of liver disease, a total of 13 
subjects would be required at a 5% significance level and 80% power. As some clinical 
values were missing due to the data having been retrospectively collected, sample size 
calculations were readjusted. Sample size calculations were performed using JMP 11.2 
Pro statistical analysis software (SAS Institute, Cary, NC).  
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RESULTS 
Clinical characteristics 
Table 1 shows the clinical characteristics of 9 control subjects, 19 SS subjects, and 23 
NASH subjects. Body mass index values were significantly higher in patients with SS 
and NASH than in the control group. According to the guidelines proposed by the 
International Obesity Task Force of the World Health Organization (IOTF-WHO), 
individuals with BMI≥25 in Asian populations are obese 28. Based on these guidelines, 
the prevalences of obesity were higher in the SS and NASH groups than in the no 
steatosis group. The prevalence of hypertension, defined as systolic blood pressure≥140 
mmHg and/or diastolic blood pressure≥90 mmHg 29, or taking antihypertensive drugs, 
also rose with progression of NAFLD (Table 1). AST and ALT levels in the SS and 
NASH groups were significantly higher than those in the control group. Serum type IV 
collagen and hyaluronic acid levels in patients with NASH were above the upper limit 
of the normal range [<140 ng/mL and <50 ng/mL, respectively]. These biochemical data 
support the pathological classification of NAFLD. HbA1c levels in the NASH group 
were significantly higher than those in the control group, although these levels did not 
exceed the upper limit of the normal range. Fasting serum insulin levels in the NASH 
group were significantly higher than those in the SS group, while fasting plasma 
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glucose levels were similar among the control, SS and NASH groups. Notably, the 
HOMA-IR of patients with SS and NASH were 3.5 ± 0.7 and, 5.3 ± 0.6, respectively, 
both above the upper limit of the normal range. These findings suggest the development 
of systemic insulin resistance in NAFLD patients.  
 
Histological liver analyses  
The histological features of the liver biopsy samples were semi-quantitatively scored 
according to the Kleiner’s scoring system 22 and Brunt’s staging classification 23 (Table 
2). Kleiner’s score consists of the degree of steatosis, lobular inflammation and 
hepatocellular ballooning and Brunt’s staging classification 23 represents the degree of 
fibrosis. The control group showed virtually no features of steatosis, lobular 
inflammation, ballooning or fibrosis. The degrees of lobular inflammation, ballooning 
and fibrosis were markedly higher in the NASH than in the SS group, while the degrees 
of steatosis were similar in these two groups.  
 
Selective resistance to the effects of insulin on hepatic gluconeogenesis suppression, 
but not lipogenesis promotion, was demonstrated in human NAFLD  
To examine the effects of insulin on gluconeogenesis suppression as well as 
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lipogenesis promotion in the livers of NAFLD patients, we selected key insulin 
signaling molecules, IRS-1 and IRS-2, and key enzymes for gluconeogenesis, PEPCK 
and G6Pase, for glycolysis, GCK, and for lipogenesis, FAS. The levels of mRNA 
expressions of IRS-1 30, IRS-2 30, PEPCK 31 and G6Pase 32 reportedly reflect their 
functions. In addition, hepatic GCK 33 and FAS 34 activities are regulated on the 
transcriptional level under steatotic conditions. Therefore, we analyzed the hepatic gene 
expressions of these molecules as well as those of IR and its isoforms (IR-A and IR-B) 
in 9 healthy control subjects, 19 SS and 23 NASH patients. Although hepatic IRS-1 
mRNA levels did not differ among the three groups (Figure 1a), hepatic IRS-2 mRNA 
levels were significantly lower in the SS and NASH groups than in the controls (Figure 
1b). Hepatic PEPCK and G6Pase mRNA expressions were significantly higher (Figure 
1c, d), while GCK mRNA expression tended to be higher, in the SS and NASH groups 
than in the controls (Figure 1e). On the other hand, hepatic FAS mRNA levels were 
significantly higher in the NASH than in the control group (Figure 1f). These findings 
using human biopsy samples indicate that IRS-2 is down-regulated, while IRS-1 
expression is unaltered, under NAFLD conditions. In addition, insulin signaling 
favoring the down-regulations of genes for gluconeogenesis was impaired, while that 
for lipogenic gene up-regulation was not impaired, instead being enhanced. Thus, 
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selective resistance to the suppressive effects of insulin on gluconeogenesis, but not 
lipogenesis promotion, was demonstrated in human NAFLD.  
The expression of IR mRNA was lowest in the controls, followed by the SS group, 
and finally highest in the NASH group (Figure 1g). However, IR-B/IR-A ratios were 
highest in the controls, followed by the SS group, and finally lowest in the NASH group 
(Figure 1h). These results suggest that IR-A was selectively up-regulated, with the 
progression of NAFLD in human subjects. 
 We further analyzed the hepatic gene expressions in 9 healthy subjects and 42 
NAFLD patients, divided into groups according to their NAFLD activity scores 22. 
There were 9 subjects with no steatosis (NAFLD activity score of 0), 11 with simple 
steatosis (1-2 points), 23 with borderline-NASH (3-4 points) and 8 with NASH (5-8 
points). Although hepatic IRS-1 mRNA levels did not differ among the four groups 
(Supplementary Figure 2a), hepatic IRS-2 mRNA levels were significantly lower in 
subjects with simple steatosis, borderline-NASH and NASH than in those with no 
steatosis (Supplementary Figure 2b). Hepatic PEPCK and G6Pase mRNA expressions 
were significantly higher (Supplementary Figure 2c, d), while GCK and FAS mRNA 
expression tended to be higher, in the simple steatosis, borderline-NASH and NASH 
groups than in the no steatosis group (Supplementary Figure 2e, f). The expression of IR 
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mRNA was significantly higher in the borderline-NASH and NASH groups than in 
those free of steatosis (Supplementary Figure 2g). However, IR-B/IR-A ratios were 
highest in the no steatosis group, followed by the simple steatosis, borderline-NASH, 
and finally lowest in the NASH group (Supplementary Figure 2h). IRS-2, PEPCK, 
G6Pase and IR expressions did not differ among the simple steatosis, borderline-NASH 
and NASH groups. The results were quite similar to those obtained using the 
classification system developed by Matteoni et al 21 (Figure 1). Collectively, these 
findings suggest that the hepatic change associated with simple steatosis, rather than 
NAFLD progression causes these alterations in the expressions of insulin signaling 
molecules and insulin-target enzymes. 
 
Hepatic IRS-1 and IRS-2 gene expressions were strongly linked to lipogenic and 
gluconeogenic gene expressions, respectively  
We next examined the relationships between IRS-1 or IRS-2 mRNA levels and 
gluconeogenesis or lipogenesis genes in all of our study subjects. Interestingly, the 
hepatic IRS-1 mRNA levels showed a strong positive association with FAS mRNA 
(r=0.64, P<0.001) (Figure 2e), but was not negatively associated with either PEPCK or 
G6Pase mRNA level. For PEPCK, IRS-1 showed a paradoxically positive association 
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(r=0.39, P=0.005) (Figure 2a). In contrast, hepatic IRS-2 mRNA levels were negatively 
associated with both PEPCK (r=-0.30, P=0.032) (Figure 2b) and G6Pase (r=-0.34, 
P=0.017) mRNA levels (Figure 2d). However, no significant association was observed 
between IRS-2 and FAS expressions. These results suggest that IRS-1 expression is 
involved in FAS up-regulation, while IRS-2 down-regulation plays important roles in 
the impaired suppression of PEPCK and G6Pase. In addition, we examined the 
relationships between IRS-1 or IRS-2 mRNA levels and the IR-B/IR-A mRNA ratio. 
However, neither IRS-1 nor IRS-2 showed any significant association with the 
IR-B/IR-A ratio (Figures 2g and 2h). Taken together, these observations indicate that 
the effects of insulin on lipogenic and gluconeogenic gene expressions are likely to be 
distinguished from each other at the IRS step and selective down-regulation of IRS-2 
may contribute to selective insulin resistance, i.e. there is an impairment adversely 
impacting the capacity of insulin to suppress gluconeogenesis. 
 
Correlations of hepatic gene expressions with clinical parameters 
We analyzed the correlations between hepatic gene expressions and clinical 
parameters (Table 3). BMI was negatively associated with IRS-2 mRNA (r=-0.32, 
P<0.01), while being positively associated with expressions of PEPCK (r=0.34, 
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P<0.05) and G6Pase (r=0.38, P<0.01). Serum AST levels were positively associated 
with G6Pase mRNA (r=0.50, P<0.01). Serum ALT levels were negatively associated 
with IRS-2 mRNA levels (r=-0.39, P<0.01), and were positively associated with 
PEPCK mRNA (r=0.30, P<0.05) and G6Pase mRNA (r=0.49, P<0.01). Serum total 
cholesterol levels were negatively associated with GCK mRNA levels (r=-0.28, 
P<0.05). 
 
Correlations of hepatic gene expressions with the histological severities of NAFLD 
components  
We next analyzed the correlations between hepatic gene expressions and histological 
severities of NAFLD components in all subjects (Table 3). The severities of steatosis 
and lobular inflammation correlated negatively with hepatic IRS-2 mRNA levels 
(r=-0.54, P<0.01, and r=-0.35, P<0.05, respectively) and positively with PEPCK 
(r=0.38, P<0.01, and r=0.33, P<0.05, respectively), and G6Pase (r=0.50, P<0.01, and 
r=0.59, P<0.01, respectively). Thus, resistance to the suppressive effects of insulin on 
gluconeogenesis apparently begins in the early phases of NAFLD. In contrast, neither 
IRS-1 nor FAS mRNA levels correlated significantly with the severity of any of the 
histological features, indicating that insulin signaling for the up-regulation of lipogenic 
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enzyme expression is independent of the histological severity of NAFLD. In addition, 
while ballooning (r=0.43, P<0.01) and fibrosis (r=0.60, P<0.01) correlated positively 
with G6Pase expression, associations with IRS-2 and PEPCK were weak or absent. 
Taken together with the finding that ALT, which was already elevated in the SS group 
(Table 1), is the parameter most strongly associated with IRS-2/PEPCK/G6Pase 
expressions (Table 3), selective insulin resistance associated with IRS-2 
down-regulation is likely to occur in the early stages of NAFLD. 
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DISCUSSION 
One of the important findings of the present study is down-regulation of IRS-2 along 
with up-regulation of PEPCK and G6Pase in humans with NAFLD. IRS-2 
down-regulation was observed in both the SS and the NASH group, but IRS expressions 
did not differ between the SS and the NASH groups. Similarly, up-regulations of 
PEPCK and G6Pase were observed in both the SS and the NASH group, but the PEPCK 
and G6Pase expressions did not differ between SS and NASH groups. Thus, IRS-2, 
PEPCK and G6Pase expressions are concurrently altered in the early stage of NAFLD. 
In animal studies using obese models such as mice fed a high-fat diet 9, 11, 35, ob/ob mice 
7, 36 and Zucker fatty rats 30, levels of IRS-2 mRNA were shown to be decreased in 
contrast to those of IRS-1. PEPCK and G6Pase are two critical rate-limiting 
gluconeogenic enzymes, the expressions of which are suppressed by insulin at the 
transcriptional level 37, but PEPCK and G6Pase mRNA levels in liver are reportedly 
increased in insulin-resistant animal models 38, 39. This led to speculation that the 
decreased IRS-2 in hepatic steatosis is the main contributor to impairment of the insulin 
signaling which governs the suppression of hepatic glucose production 40. On the other 
hand, human data on the hepatic expressions of IRS-2, PEPCK, and G6Pase in NAFLD 
are scarce and no consensus has yet been obtained. For instance, IRS-2 mRNA 
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expression in liver biopsy samples from NAFLD 9, 12 and NASH 13 subjects were 
reported to be lower than in those from subjects with normal livers, while there is a 
report indicating that IRS-2 mRNA expression increased progressively with the severity 
of NASH 14. There is a report indicating PEPCK and G6Pase mRNA levels in liver 
biopsy samples from NASH patients to be higher than in the normal liver 15, while 
G6Pase mRNA expression was reported to be lower in liver biopsy samples from 
NAFLD patients 16. Furthermore, to our knowledge, no studies have analyzed the 
associations among IRSs and these key molecules for gluconeogenesis and lipogenesis 
in human liver. 
In the present study, we examined mRNA expressions of key molecules for insulin 
signaling, gluconeogenesis and lipogenesis in human liver biopsy samples and analyzed 
associations of these molecules with each other and with detailed pathological and 
clinical biochemistry data. Hepatic IRS-2 mRNA was significantly lower in SS and 
NASH patients than in controls, while hepatic PEPCK and G6Pase mRNA levels in the 
SS and NASH patients were significantly higher than those in the control group. 
Moreover, most importantly, hepatic IRS-2 mRNA levels were negatively associated 
with PEPCK and G6Pase mRNA. Thus, our integrated analyses of multiple gene 
expressions suggest that decreased IRS-2 plays an important role in the development of 
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hepatic insulin resistance in humans with NAFLD. Protein expressions were not 
examined, which is a limitation of this study, due to the small amounts of liver biopsy 
material available. However, mRNA expression the levels of these key molecules, 
including IRS-1 30, IRS-2 30, PEPCK 31, G6Pase 32, GCK 33 and FAS 34, reportedly 
reflect their functions. In addition, insulin is well known to affect these key metabolic 
enzymes at mRNA expression levels. Therefore, analyses of mRNA expression levels 
may allow a conclusion to be drawn as to whether selective insulin resistance occurs in 
human NAFLD. Our human findings are consistent with those obtained from 
experimental animal models with hepatic steatosis and obesity. Therefore, the results 
obtained from experiments using animal models are likely to also hold true for the 
pathophysiology of human hepatic insulin resistance. 
In addition, there were no differences in the expressions of IRS-2, PEPCK or G6Pase 
between the SS and the NASH groups in this study. The decrease in IRS-2 and the 
increases in PEPCK and G6Pase were associated with the histological degrees of 
steatosis and lobular inflammation, although IRS-2 was not associated with the degree 
of either fibrosis or ballooning. Moreover, serum liver enzymes were associated with 
hepatic expressions of IRS-2, PEPCK and G6Pase. In previous studies, the controls 
were morbidly obese subjects 14 and patients with elevated liver enzymes 16. In contrast, 
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our control group consisted of healthy living donors for liver transplantation, in whom 
normal biochemical liver markers and histological findings had been confirmed. Thus, 
our integrated analyses of human NAFLD cases, including pathological scoring, 
biochemical data and gene expression data, and detailed comparisons with healthy 
controls enabled us to show that alterations in IRS-2, PEPCK and G6Pase expressions 
are concurrently induced in the early stage of NAFLD, when histological steatosis and 
lobular inflammation, but not ballooning and fibrosis, manifest. 
Another important finding of the present study is that selective insulin resistance was 
demonstrated and differential contributions of IRS-1 and IRS-2 were suggested in 
human NAFLD subjects. FAS mRNA levels tended to be increased in the SS group 
and were significantly increased in the NASH group, indicating that insulin signaling 
for lipogenesis is activated in NAFLD despite impaired suppression of gluconeogenetic 
enzymes. Insulin reportedly increases SREBP-1c gene expression and activates 
SREBP-1c proteolytic cleavage in the liver 41. After proteolytic cleavage, the mature 
N-terminal SREBP-1c translocates into the nucleus, where it binds to SRE of the FAS 
promoter. FAS is transcriptionally regulated by SREBP-1c in response to insulin 41 . 
Through this mechanism, insulin signals may up-regulate FAS in the liver. Indeed, FAS 
expression, as well as, that of SREBP-1c is reportedly increased in subjects with 
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NAFLD 42. The present study suggests that IRS-1, rather than IRS-2, is involved in the 
insulin-mediated FAS upregulation in hepatocytes. In contrast to IRS-2, no significant 
differences were observed in IRS-1 expressions among the control, SS and NASH 
groups. It should be noted that FAS expression correlated strongly with IRS-1, 
suggesting that IRS-1 signaling plays an important role in FAS expression. Furthermore, 
no histological scores were associated with either IRS-1 or FAS, suggesting that IRS-1 
signaling is not impaired in patients with NAFLD. Taken together with the report 
indicating the role of IRS-1 as the inducer of GCK and SREBP-1c, shown in rat 
hepatocytes 43 and liver-specific IRS-1 knockout mice 44, persistent expression of IRS-1 
and hyperinsulinemia in NAFLD may enhance FAS up-regulation in the steatotic liver. 
These results indicate that insulin signaling for lipogenesis via IRS-1 is maintained 
despite impairment of the insulin signaling which favors suppression of 
gluconeogenesis via IRS-2 (Figure 3). To the best of our knowledge, this is the first 
report showing selective insulin resistance in the human liver and further indicating that 
the differences in the expression patterns of IRS-1 and IRS-2 are likely to be involved in 
the underlying mechanism. During preparation of this manuscript, it was reported that 
hepatic IRS-2 knockout mice develop selective insulin resistance 9. The study, 
employing the murine gene targeting technique, supports our findings in humans. 
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We have obtained novel findings shedding light on IR expression in the liver. In our 
study, hepatic IR expressions were higher in the SS and NASH groups than in the 
controls. IR mRNA has two isoforms due to alternative splicing variation of exon 11 of 
the IR gene. These IR isoforms can form either homodimers (IR-A/IR-A, IR-B/IR-B) or 
a heterodimer (IR-A/IR-B). The IR-A (exon 11-) isoform reportedly has a mitogenic 
property, while the IR-B (exon 11+) isoform is predominantly involved in glucose 
metabolism 45. IR-B is reported to be the dominant (approximately 80%) isoform in the 
human liver 46 but IR-A/IR-A 45 and the IR-A/IR-B 47 have higher affinities for IGF-II 
than IR-B/IR-B. In our study, similar results were obtained in healthy controls but the 
IR-B/IR-A ratio was significantly decreased in the SS and NASH groups. The increase 
in the proportion of IR-A may stimulate mitogenic signaling, which might contribute to 
carcinoma development, one of the major complications of NAFLD, although further 
studies are needed to elucidate the actions of these IR isoforms in NAFLD patients. In 
addition, a decrease in the proportion of IR-B may also contribute to the development of 
hepatic insulin resistance which would in turn impact glucose metabolism.  
In the present study, we examined hepatic gene expressions of key molecules 
involved in insulin signaling, lipogenesis and gluconeogenesis in both healthy subjects 
and patients with NAFLD. Our integrated analyses encompassed both these findings 
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and detailed pathological and clinical biochemistry data. These analyses revealed that 
selective insulin resistance occurs in the human liver, and that differential expression 
patterns of IRS-1 and IRS-2 may contribute to the underlying mechanism. In addition, 
the IR-A isoform was up-regulated in NAFLD patients. Collectively, these results are 
significant for understanding the pathophysiology of NAFLD and its associated 
metabolic disorders. 
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Figure Legend 
 
Figure 1. Gene expression levels in the livers of the three groups. 
The hepatic gene expression levels were compared among the control, SS, and NASH 
groups. Individual genes are normalized to CDKN1B mRNA levels. IRS-1 (a), IRS-2 
(b), PEPCK (c), G6Pase (d), GCK (e), FAS (f), IR (g), and IR-B/IR-A ratio (h).  Data 
from 51 human liver biopsies are shown. The top and bottom of each box indicate the 
1st and 3rd quartiles (interquartile range, IGR), and the band inside the box is the median. 
The ends of the whiskers represent the minima and maxima without outliers. The value 
of P was determined by ANOVA with Tukey-Kramer post hoc testing. (*P<0.05, 
**P<0.01). 
 
Figure 2. Hepatic IRS-1 and IRS-2 mRNA levels correlated with gluconeogenesis 
and lipogenesis gene expressions. 
The scatter plots show the relationship of IRS-1 mRNA levels with PEPCK (a) or 
G6Pase (c) or FAS (e) mRNA levels or the IR-B/IR-A mRNA ratio (g), and the 
relationship of IRS-2 mRNA levels with PEPCK (b) or G6Pase (d) or FAS (f) mRNA 
levels or the IR-B/IR-A mRNA ratio (h). Data from 51 human liver biopsies are shown. 
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Gene expressions are normalized to CDKN1B mRNA levels. The lines indicate the 
linear regressions between the parameters. The value of P was determined by Pearson’s 
test.  
 
Figure 3. Insulin signaling in the liver of subjects with normal liver and NAFLD. 
The expression of insulin receptor substrates-2 (IRS-2) is decreased, while the 
expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(G6Pase) are increased in patients with NAFLD. In contrast, the expression of IRS-1 is 
unaltered and the expression of fatty acid synthase (FAS) is increased in patients with 
NAFLD. 
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Table 1. Anthropometric and biochemical data 
 
 Control SS NASH 
Male / female (n) 6 / 3 13 / 6 8 / 15 
Age (years) 36.4 ± 4.3 47.5 ± 3.0 55.3 ± 3.0B 
Body mass index (kg/m2) 22.0 ± 1.3 27.3 ± 0.9B 27.3 ± 0.8B 
Prevalence of obesity (%) 11.1 68.4 78.3 
Prevalence of hypertension (%)E 0.0 25.0 39.1 
HbA1c (%)F 5.3 ± 0.1 5.7 ± 0.1 5.8 ± 0.1A 
HbA1c (mmol/mol)F 34.4 ± 1.3 38.6 ± 1.0 40.1 ± 1.0A 
Fasting plasma glucose (mg/dL) 93.0 ± 3.4 96.9 ± 2.3 98.6 ± 2.1 
Fasting serum insulin (µU/mL)G - 13.9 ± 2.8 21.9 ± 2.3C 
HOMA-IRG - 3.5 ± 0.7 5.3 ± 0.6C 
AST (IU/L) 17.6 ± 8.1 36.7 ± 5.6B 67.3 ± 4.3B 
ALT (IU/L) 18.0 ± 13.0 67.8 ± 9.0B 74.8 ± 6.9B 
Total cholesterol (mg/dL) 187.8 ± 10.0 210.4 ± 9.9 185.3 ± 9.0 
Triglycerides (mg/dL) 104.2 ± 24.1 158.1 ± 16.6 144.5 ± 15.2 
Serum type IV collagen (ng/mL)H - 94.6 ± 17.7 162.3 ± 11.7D 
Serum hyaluronic acid (ng/mL)I - 48.0 ± 43.5 105.6 ± 25.5 
 
Abbreviations: HOMA-IR, homeostatic model assessment insulin resistance; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; SS, simple steatosis; NASH, non-alcoholic 
steatohepatitis. 
Data are means ± SEM or numbers (n).  
P was determined by ANOVA with Tukey-Kramer post hoc testing.  
AP<0.05 versus Control 
BP<0.01 versus Control 
CP<0.05 versus SS 
DP<0.01 versus SS 
EAvailable for all 9 control subjects, 12 of the 19 SS subjects and 22 of 23 NASH subjects. 
FAvailable for 6 of the 9 control subjects, 17 of the 19 SS subjects and all 23 NASH subjects. 
GAvailable for 16 of the 19 SS subjects and all 23 NASH subjects. 
HAvailable for 8 of the 19 SS subjects and 18 of the 23 NASH subjects. 
IAvailable for 7 of the 19 SS subjects and 21 of the 23 NASH subjects. 
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Table 2. Histological characteristics 
 
Histological 
feature 
Score 
Control (n = 9) SS (n = 19) NASH (n = 23) 
Number of biopsies (%) 
Steatosis 
0 = None (<5%) 9 (100%) 0 (0.0%) 0 (0.0%) 
1 = Mild (5-33%) 0 (0.0%) 11 (57.9%) 14 (60.9%) 
2 =Moderate (>33-66%) 0 (0.0%) 6 (31.6%) 9 (39.1%) 
3 = Severe (>66%) 0 (0.0%) 2 (10.5%) 0 (0.0%) 
Lobular 
inflammation 
0 = No foci 9 (100%) 1 (5.3%) 0 (0.0%) 
1 = <2 foci 0 (0.0%) 15 (78.9%) 11 (47.8%) 
2 = 2-4 foci 0 (0.0%) 3 (15.8%) 11 (47.8%) 
3 = >4 foci 0 (0.0%) 0 (0.0%) 1 (4.0%) 
Ballooning 
0 = None 9 (100%) 15 (78.9%) 1 (4.3%) 
1 = Few balloon cells 0 (0.0%) 4 (21.1%) 17 (73.9%) 
2 = Prominent ballooning 0 (0.0%) 0 (0.0%) 5 (21.7%) 
Fibrosis 
0 = No 9 (100%) 5 (26.3%) 0 (0.0%) 
1 = Mild, perisinusoidal 0 (0.0%) 11 (57.9%) 2 (8.7%) 
2 = Perisinusoidal and 
portal/periportal 
0 (0.0%) 3 (15.8%) 6 (26.1%) 
3 = Bridging fibrosis 0 (0.0%) 0 (0.0%) 10 (43.5%) 
4 = Cirrhosis 0 (0.0%) 0 (0.0%) 5 (21.7%) 
 
Abbreviations: SS, simple steatosis; NASH, non-alcoholic steatohepatitis. 
The distributions of the patients according to the degrees of steatosis, lobular inflammation, 
ballooning and fibrosis are presented as absolute numbers (n) and percentages (%) for all 51 
subjects in this study. 
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